Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)
The protein has a calculated MW of 61.0 kDa. The protein migrates as 80-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Cynomolgus IL-12 R beta 1 , His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Biotinylated Cynomolgus IL-12 R beta 1 , His,Avitag (Cat. No. ILB-C52E2) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human IL-12B, Fc Tag (Cat. No. NK2-H5258) with a linear range of 0.1-8 ng/mL (QC tested).
Loaded Biotinylated Cynomolgus IL-12 R beta 1 , His,Avitag (Cat. No. ILB-C52E2) on SA Biosensor, can bind ActiveMax® Human IL-12 ,Tag Free (Cat. No. IL2-H5210) with an affinity constant of 1.9 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Price(USD) : $360.00
Price(USD) : $1420.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ustekinumab biosimilar (Samsung Bioepis) | SB-17; SB17 | Approved | Samsung Bioepis Co Ltd | Pyzchiva | EU | Crohn Disease; Colitis, Ulcerative | Samsung Bioepis Nl Bv | 2024-04-19 | Gastrointestinal Diseases; Skin Diseases; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic; Rheumatic Diseases; Inflammation; Crohn Disease; Plaque psoriasis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
KLT-1101 | KLT-1101 | Phase 2 Clinical | Kang Litai Pharmaceutical Co Ltd | Solid tumours; Leukopenia; Thrombocytopenia; Melanoma; Sarcoma, Kaposi | Details |
Edodekin alfa | RO 247472; YM 01C | Phase 2 Clinical | Wistar Institute, Valeant, F. Hoffmann-La Roche Ltd | Hepatitis B; Melanoma; Bacterial Infections; Sarcoma, Kaposi; Leishmaniasis; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Asthma; Hepatitis C; Solid tumours; Breast Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Graft vs Host Disease; Squamous Cell Carcinoma of Head and Neck; Abdominal Neoplasms; Carcinoma, Renal Cell; Malaria; HIV Infections | Details |
IMNN-001 | IMNN-001; phIL-12-005/PPC; GEN-1; EGEN-001 | Phase 2 Clinical | Expression Genetics | Cystadenocarcinoma; Ovarian Neoplasms; Cystadenocarcinoma, Serous; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Endometrioid | Details |
RTX-224 | RTX-224 | Phase 2 Clinical | Rubius Therapeutics Inc | Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
SON-1010 | SON-1010 | Phase 2 Clinical | Sonnet Biotherapeutics Inc | Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
KB-707 | KB707; KB-707 | Phase 2 Clinical | Krystal Biotech Inc | Solid tumours; Skin Melanoma; Neoplasms; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
ANK-101 | ANK101; ANK-101 | Phase 1 Clinical | Ankyra Therapeutics Inc | Solid tumours; Soft Tissue Injuries; Skin Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
CLN-617 | CLN-617 | Phase 1 Clinical | Cullinan Therapeutics Inc | Solid tumours | Details |
phIL12 GET | Phase 1 Clinical | Institute Of Oncology Ljubljana | Carcinoma, Basal Cell | Details | |
Encapsulated pancreatic cancer vaccine(Therapyx) | PCX-12 | Phase 1 Clinical | TherapyX Inc | Pancreatic Neoplasms | Details |
This web search service is supported by Google Inc.